Inscripta

OverviewSuggest Edit

Inscripta is a company that develops a benchtop platform for scalable digital genome engineering. The company’s CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables trackable editing of single cells. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations.
TypePrivate
Founded2015
HQBoulder, CO, US
Websiteinscripta.com
Employee Ratings4.9

Latest Updates

Employees (est.) (May 2022)191(+2%)
Job Openings16
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Inscripta

Michael Graige

Michael Graige

Chief Technical Officer
Todd Rubano

Todd Rubano

VP, Informations Systems and Software
Ron McGrath

Ron McGrath

Chief Financial Officer
Tom Rosso

Tom Rosso

Vice President, Operations
Elizabeth Holland

Elizabeth Holland

Vice President, Human Resources
Paul Hardenbol

Paul Hardenbol

Vice President, Biology
Show more

Inscripta Office Locations

Inscripta has offices in Boulder, Pleasanton, Poway, San Diego and in 1 other location
Boulder, CO, US (HQ)
5500 Central Ave #220
Pleasanton, CA, US
5720 Stoneridge Dr #300
Pleasanton, CA, US
7026 Koll Center Pkwy #225
Poway, CA, US
12740 Danielson Ct suite f
San Diego, CA, US
5764 Pacific Center Blvd
København, DK
Tagensvej 22
Show all (6)

Inscripta Financials and Metrics

Summary Metrics

Founding Date

2015

Inscripta total Funding

$409.5 m

Inscripta latest funding size

$150 m

Time since last funding

a year ago

Inscripta investors

Inscripta's latest funding round in April 2021 was reported to be $150 m. In total, Inscripta has raised $409.5 m
Show all financial metrics

Inscripta Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Inscripta Online and Social Media Presence

Embed Graph

Inscripta News and Updates

$125 million for Inscripta may usher in the next wave of genetic engineering

In these waning days of the second decade of the twenty-first century, technologists and investors are beginning to lay the foundations for new, truly transformational technologies that have the potential to reshape entire industries and rewrite the rules of human understanding. It may sound lofty, …

Inscripta Hires Chief Commercial Officer Jason T. Gammack to Bring Gene-Editing Tools to Market

BOULDER, Colo., Nov. 1, 2018 /PRNewswire/ -- Inscripta™, a leading gene-editing technology company, today announced the addition of Jason T. Gammack as the company's first chief commercial officer. Gammack, a 25-year veteran of life sciences commercial operations, will leverage his...

Meet the Startup That's Giving Away Its CRISPR-Like Technology For Free

CRISPRis one of the most promising areas in biotech, but much of that potential has been locked behind expensive licensing schemes.

Inscripta Blogs

Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy

Inscripta today named Jim Lalonde, Ph.D. to its management team The post Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy appeared first on Inscripta.

Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts

World’s first benchtop platform for scalable digital genome engineering to be launched at SynBioBeta conference in October The post Inscripta Expands Management Team with Appointment of Three Senior Bioinformatics and Computational Biology Experts appeared first on Inscripta.

Inscripta to Present First Data From Its Digital Genome Engineering Technology at Upcoming Synthetic Biology Conference

Results from a 200,000-edit library of an E. coli biosynthesis pathway show unprecedented scale and variety of edit types The post Inscripta to Present First Data From Its Digital Genome Engineering Technology at Upcoming Synthetic Biology Conference appeared first on Inscripta.

Inscripta Appoints Ron McGrath as Chief Financial Officer

Boulder, CO – April 30, 2019 – Inscripta, developer of the first scalable platform for benchtop Digital Genome Engineering, today announced the appointment of Ron McGrath as Chief Financial Officer. Mr. McGrath has held leadership and financial roles for more than 25 years in the biotechnology and i…

Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M

Continued support of existing investors will fund commercialization efforts, product launch later this year The post Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M appeared first on Inscripta.

In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community

Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research The post In the First Year of Release, Inscripta’s MAD7 CRISPR Enzyme is Widely Adopted by the Gene-Editing Community appeared first on Inscripta.
Show more

Inscripta Frequently Asked Questions

  • When was Inscripta founded?

    Inscripta was founded in 2015.

  • Who are Inscripta key executives?

    Inscripta's key executives are Michael Graige, Todd Rubano and Ron McGrath.

  • How many employees does Inscripta have?

    Inscripta has 191 employees.

  • Who are Inscripta competitors?

    Competitors of Inscripta include Dyne Therapeutics, Freeline and GenePlanet.

  • Where is Inscripta headquarters?

    Inscripta headquarters is located at 5500 Central Ave #220, Boulder.

  • Where are Inscripta offices?

    Inscripta has offices in Boulder, Pleasanton, Poway, San Diego and in 1 other location.

  • How many offices does Inscripta have?

    Inscripta has 6 offices.